More than 1 billion varieties The Shanghai-owned company won its first new product of the year.

Pharmaceutical network August 17th, August 14th, the official website of the State Drug Administration shows that Shanghai Abison with imitation of 4 categories of reported hydrochloric acid Tansorosin slow release capsules were approved for listing and regarded as the same review.
2019, China's public medical institutions terminal sales of more than 1 billion yuan, four enterprises have been evaluated products.
Tansorosin belongs to the selective alpha1 epinephrine receptament blocker, which is used clinically to treat urination disorders caused by prostate hyperpluria by selectively blocking alpha1A epinephrine receptors in the prostate and relaxing the smooth muscle of the prostate, thus improving the urination difficulties caused by benign prostate hyperplative disorders.
At present, there are 6 enterprises in the domestic market with hydrochloric acid Tansorosin slow release capsule production approval, Minenet data show that the product in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) terminal sales of more than 1 billion yuan, the original research manufacturer Astellas Pharmaceuticals accounted for more than 60% of the market share. Table
: The consistency evaluation of hydrochloric acid Tansorosin slow release capsules carried out source: Minet consistency evaluation Kuminnet data show that 6 domestic enterprises layout hydrochloric acid Tansorosin slow release capsule consistency evaluation, Hangzhou Kangnbei Pharmaceuticals, Zhejiang Helisheng Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals 3 enterprises submitted consistency Evaluation of supplementary applications, has been successfully evaluated, Jiangxi Shanxiang Pharmaceuticals, Guangdong South China Pharmaceuticals, Shanghai Abisan Pharmaceuticals 3 enterprises to copy 4 categories to submit the product listing application, of which Shanghai Abison Pharmaceutical products have been successfully approved and treated as the same, the product is the first Shanghai Abisan Pharmaceuticals approved this year generic drugs.
source: In-net database note: data statistics as of August 14, if there are omissions, welcome to point the right!